Senti Biosciences (NASDAQ:SNTI) Stock Price Down 3.8% – What’s Next?

Senti Biosciences, Inc. (NASDAQ:SNTI) traded down 3.8% during trading on Tuesday . The stock traded as low as $0.9057 and last traded at $0.9057. 178,419 shares traded hands during mid-day trading, a decline of 12% from the average session volume of 202,477 shares. The stock had previously closed at $0.9416.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Chardan Capital boosted their price objective on shares of Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Tuesday, April 21st. Finally, Wall Street Zen upgraded shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Senti Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Senti Biosciences Stock Performance

The firm has a market capitalization of $28.21 million, a PE ratio of -0.47 and a beta of 2.08. The firm has a fifty day moving average of $0.96 and a 200 day moving average of $1.10.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.22. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Research analysts forecast that Senti Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in Senti Biosciences in the fourth quarter worth $46,000. Jane Street Group LLC acquired a new position in shares of Senti Biosciences during the fourth quarter valued at $40,000. Citadel Advisors LLC acquired a new position in shares of Senti Biosciences during the third quarter valued at $117,000. Armistice Capital LLC bought a new position in shares of Senti Biosciences during the second quarter worth about $1,883,000. Finally, Geode Capital Management LLC grew its position in shares of Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares during the last quarter. 25.70% of the stock is currently owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.